The treatment of 2-(ArN═CH)C 6 H 4 -HNC 9 H 6 N ( [N Q N A N I Me ]H, Ar = 2,6-Me 2 C 6 H 3; [N Q N A N I Et ]H, Ar = 2,6-Et 2 C 6 H 3; [N Q N A N I iPr ]H, Ar = 2,6- i Pr 2 C 6 H 3 ) with n BuLi and CrCl 3 (THF) 3 achieves the hetero-dinuclear complexes [N Q N A N I R ] CrCl(μ-Cl) 2 Li(THF) 2 ( 1a, R = Me; 1b, R = Et; 1c, R = i Pr) or bisligated complex κ 5 - [N Q N A N I iPr ] 2 CrCl ( 2c ) depending on the reactant ratios used. Reactions of these ligands with n BuLi and CrCl 2 (THF) 2 could achieve the square-pyramidal complexes [N Q N A N I R ] CrCl(THF) ( 3b, R = Et; 3c, R = i Pr). Complex 3c can be oxidized by alkyl chloride to dimeric complex { [N Q N A N I iPr ] CrCl} 2 (μ-Cl) 2 ( 4 ) through a single-electron-transfer mechanism. Similar reaction of 2-(C 9 H 6 N)N═CHC 6 H 4 -HNAr ( [N Q N I N A Me ]H, Ar = 2,6-Me 2 C 6 H 3; [N Q N I N A Et ]H, Ar = 2,6-Et 2 C 6 H 3; [N Q N I N A iPr ]H, Ar = 2,6- i Pr 2 C 6 H 3 ) with n BuLi and CrCl 3 (THF) 3 furnishes [N Q N I N A R ] CrCl(μ-Cl) 2 Li(THF) 2 ( 5a, R = Me; 5b, R = Et; 5c, R = i Pr) in high yields. However, a chromium complex with a butyl-substituted ligand, [N Q Bu N I N A iPr ] CrCl 2 ( 6 ), is obtained when 2 equiv of n BuLi is used. The molecular structures of 1c, 2c, 3c, 4, 5c, and 6 are confirmed by X-ray crystallography. Upon activation with MAO, the Cr(III) complexes ( 1a – 1c, 4, and 5a – 5c ) show moderate catalytic activities (50 to 218 kg of PE·mol(Cr) −1 ·h –1 ) in ethylene polymerization, whereas the Cr(II) complexes 2c, 3b, and 3c are inert under the same conditions.
No takes yet. Share an insight, caveat, or question.
Hao et al. (2015) studied this question.
Synapse has enriched 4 closely related papers on similar clinical questions. Consider them for comparative context: